Chimeric antigen receptor T-cell therapy is an immunotherapeutic approach that has yielded favorable outcomes in various hematologic malignancies. Educating oncology nurses on how to recognize serious adverse events, such as cytokine release syndrome (CRS), is critical for early intervention and reducing CRS-related deaths.
Breast cancer is the second leading cause of cancer-related deaths in women in the United States. Despite the increase in survival with trastuzumab in the adjuvant setting, up to 26% of patients with early-stage HER2+ breast cancer experience disease recurrence within 5 to 8 years. The interim analysis after 5 years of follow-up in the ExteNET trial is presented.
Adherence to prescribed therapy is pivotal in cancer treatment. To ensure that patients receive the full benefit of their prescribed therapy, nurses and nurse practitioners play a critical role in identifying adverse events and implementing effective interventions that balance efficacy and tolerability.
Nivolumab is an immune checkpoint inhibitor approved for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma. This immunotherapeutic agent is associated with immune-related adverse events that require prompt identification for successful management and resolution.
The use of monoclonal antibodies in the treatment of cancer is rapidly evolving. These immunomodulating agents are associated with an increased incidence of hypersensitivity reaction. Prompt identification and effective management is essential for optimal patient care.
Blinatumomab is the only single-agent therapy approved for patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This bispecific antibody induces complete remission, as well as serious adverse events, including central nervous system toxicities and cytokine release syndrome. Oncology nurses play a critical role in early identification and intervention of these toxicities.
Small-cell lung cancer (SCLC) is a highly aggressive form of lung cancer associated with high mortality rates. Most patients experience relapse after first-line therapy, and there is no approved drug after second-line therapy. With immune checkpoint therapies rapidly becoming the standard of care in the second-line treatment of metastatic non–small-cell lung cancer, there is tremendous hope that these agents will prove effective in SCLC.
Immunotherapy represents a new era in the treatment of cancer patients. Immunomodulating agents increase overall survival and induce highly durable tumor responses in a rapidly expanding patient population. In this dynamic and rapidly evolving landscape, there is significant need to educate nurses and patients on this therapeutic class and its associated toxicities.
Chimeric antigen receptor (CAR) T-cell therapy is an immunotherapeutic approach used in the treatment of various hematologic malignancies. CAR T-cell therapy utilizes gene transfer to reprogram the patient’s own T-cells to recognize and target tumor-associated antigens. Although groundbreaking and incredibly efficacious, CAR T-cell therapy has serious side effects that require prompt identification and intervention.